EGFR and non-small cell lung carcinoma: The third-generation EGFR-TKI os imertinib has been developed to overcome the acquired T790M mutation and has been approved as a first-line drug for treating advanced EGFR-mutated NSCLC, but tumoral clone resistance often occurs after 6–17 months treatment (Wang et al., 2016; Mok et al., 2017; Tan et al., 2018; Solassol et al., 2019).